Charles Schwab
IMGN

Charles Schwab’s Immunogen Inc IMGN Stock Holding History

Charles Schwab’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,892,446
Closed -$56.1M – 3555
2023
Q4 		$56.1M Buy
1,892,446
+61,871
+3% +$1.23M 0.01% 884
2023
Q3 		$29.1M Buy
1,830,575
+20,113
+1% +$334K 0.01% 1246
2023
Q2 		$34.2M Buy
1,810,462
+251,441
+16% +$2.97M 0.01% 1130
2023
Q1 		$5.99M Sell
1,559,021
-2,563
-0.2% -$10.9K ﹤0.01% 2125
2022
Q4 		$7.75M Buy
1,561,584
+36,478
+2% +$198K ﹤0.01% 1994
2022
Q3 		$7.29M Buy
1,525,106
+60,887
+4% +$321K ﹤0.01% 2015
2022
Q2 		$6.59M Sell
1,464,219
-36,000
-2% -$156K ﹤0.01% 2061
2022
Q1 		$7.14M Buy
1,500,219
+78,296
+6% +$433K ﹤0.01% 2110
2021
Q4 		$10.6M Buy
1,421,923
+15,921
+1% +$98.9K ﹤0.01% 1973
2021
Q3 		$7.97M Sell
1,406,002
-56,233
-4% -$325K ﹤0.01% 2138
2021
Q2 		$9.64M Buy
1,462,235
+24,635
+2% +$172K ﹤0.01% 2025
2021
Q1 		$11.6M Buy
1,437,600
+209,964
+17% +$1.71M ﹤0.01% 1865
2020
Q4 		$7.92M Buy
1,227,636
+87,663
+8% +$511K ﹤0.01% 1991
2020
Q3 		$4.1M Sell
1,139,973
-20,122
-2% -$81.2K ﹤0.01% 2173
2020
Q2 		$5.34M Buy
1,160,095
+85,155
+8% +$362K ﹤0.01% 1996
2020
Q1 		$3.67M Buy
1,074,940
+171,445
+19% +$750K ﹤0.01% 1988
2019
Q4 		$4.61M Buy
903,495
+18,910
+2% +$64.2K ﹤0.01% 2056
2019
Q3 		$2.14M Buy
884,585
+26,222
+3% +$69.6K ﹤0.01% 2353
2019
Q2 		$1.86M Buy
858,363
+23,962
+3% +$56.7K ﹤0.01% 2393
2019
Q1 		$2.26M Sell
834,401
-9,016
-1% -$39.1K ﹤0.01% 2329
2018
Q4 		$4.05M Sell
843,417
-28,420
-3% -$172K ﹤0.01% 2010
2018
Q3 		$8.26M Buy
871,837
+105,881
+14% +$1.02M 0.01% 1764
2018
Q2 		$7.45M Buy
765,956
+234,880
+44% +$2.48M 0.01% 1782
2018
Q1 		$5.59M Buy
531,076
+8,112
+2% +$80.1K ﹤0.01% 1881
2017
Q4 		$3.35M Buy
522,964
+81,519
+18% +$503K ﹤0.01% 2119
2017
Q3 		$3.38M Buy
441,445
+109,547
+33% +$728K ﹤0.01% 2077
2017
Q2 		$2.36M Buy
331,898
+1,919
+0.6% +$8.78K ﹤0.01% 2166
2017
Q1 		$1.28M Sell
329,979
-68,789
-17% -$201K ﹤0.01% 2350
2016
Q4 		$814K Buy
398,768
+10,164
+3% +$20.4K ﹤0.01% 2495
2016
Q3 		$1.04M Buy
388,604
+87,648
+29% +$255K ﹤0.01% 2402
2016
Q2 		$927K Buy
300,956
+5,874
+2% +$36.8K ﹤0.01% 2373
2016
Q1 		$2.52M Buy
295,082
+4,083
+1% +$34.5K ﹤0.01% 1924
2015
Q4 		$3.95M Sell
290,999
-10,063
-3% -$124K 0.01% 1679
2015
Q3 		$2.89M Buy
301,062
+17,781
+6% +$260K ﹤0.01% 1838
2015
Q2 		$4.07M Buy
283,281
+8,420
+3% +$92.5K 0.01% 1684
2015
Q1 		$2.46M Buy
274,861
+13,206
+5% +$95.7K ﹤0.01% 1939
2014
Q4 		$1.6M Buy
261,655
+33,190
+15% +$304K ﹤0.01% 2138
2014
Q3 		$2.42M Sell
228,465
-3,740
-2% -$42.3K ﹤0.01% 1853
2014
Q2 		$2.75M Sell
232,205
-850
-0.4% -$10.7K ﹤0.01% 1803
2014
Q1 		$3.48M Buy
233,055
+12,831
+6% +$202K 0.01% 1612
2013
Q4 		$3.23M Buy
220,224
+18,987
+9% +$292K 0.01% 1602
2013
Q3 		$3.49M Buy
201,237
+8,382
+4% +$147K 0.01% 1463
2013
Q2 		$3.32M Buy
+192,855
New +$3.13M 0.01% 1386

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Charles Schwab's IMGN Position: Q1 2024 in Review

Charles Schwab sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,892,446 shares — an estimated $56.1M sold.

Charles Schwab first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $56.1M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Charles Schwab reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 1,892,446 Immunogen Inc shares in Q1 2024, an estimated $56.1M.
  • Charles Schwab first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Charles Schwab's Immunogen Inc position peaked at $56.1M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.